{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:48:10Z","timestamp":1791827290839,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974451"],"award-info":[{"award-number":["81974451"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2025JJ60742"],"award-info":[{"award-number":["2025JJ60742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    PARP inhibitors (PARPi) selectively target cancers with homologous recombination deficiency (HRD), yet emerging evidence suggests that additional determinants beyond BRCA\/HRD status modulate PARPi response. Here, by integrating unbiased proteomic profiling with systematic drug-response phenotyping across 11 ovarian cancer cell lines, we identify MAP2K6 as a previously unrecognized regulator of PARP1 activation and an important determinant of PARP inhibitor sensitivity in BRCA-wild-type ovarian cancer. MAP2K6 promotes global PARP1-mediated PARylation and enhances cellular responsiveness to the PARP inhibitor olaparib both in vitro and in vivo. Mechanistically, MAP2K6 can phosphorylate and activate HMGA1, which in turn transcriptionally upregulates NAMPT, resulting in increased intracellular NAD\n                    <jats:sup>+<\/jats:sup>\n                    levels, and sustained PARP1 activation. Genetic depletion of HMGA1 or NAMPT abolishes MAP2K6-driven PARylation and PARPi sensitization, whereas loss of MAP2K6 reduces NAD\n                    <jats:sup>+<\/jats:sup>\n                    levels, attenuates PARP1 activation, and confers resistance to PARPi. We propose that MAP2K6 promotes PARP inhibitor sensitivity by coupling metabolic control of NAD\n                    <jats:sup>+<\/jats:sup>\n                    supply to PARP1 activation, thereby potentially helping extend the therapeutic scope of PARP inhibition beyond homologous recombination-deficient ovarian cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09104-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:24:52Z","timestamp":1784265892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MAP2K6 reprograms NAD+ metabolism via the HMGA1\u2013NAMPT axis to sensitize ovarian cancer cells to PARP inhibition"],"prefix":"10.1038","volume":"17","author":[{"given":"Ming","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-847X","authenticated-orcid":false,"given":"Mingwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuran","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-5250","authenticated-orcid":false,"given":"Lunquan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-8668","authenticated-orcid":false,"given":"Rong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"9104_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"9104_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44178-023-00068-3","volume":"3","author":"L Li","year":"2024","unstructured":"Li L, Lang J. Recent advances in the treatment for gynecologic oncology. Holist Integr Oncol. 2024;3:1.","journal-title":"Holist Integr Oncol"},{"key":"9104_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"9104_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"9104_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"9104_CR6","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo Y, et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187:4905\u201325.e4924.","journal-title":"Cell"},{"key":"9104_CR7","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1101\/gad.1331805","volume":"19","author":"MY Kim","year":"2005","unstructured":"Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: \u2018PAR-laying\u2019 NAD+ into a nuclear signal. Genes Dev. 2005;19:1951\u201367.","journal-title":"Genes Dev"},{"key":"9104_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","volume":"5","author":"N Xie","year":"2020","unstructured":"Xie N, et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5:227.","journal-title":"Signal Transduct Target Ther"},{"key":"9104_CR9","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1038\/s41388-025-03428-7","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, et al. The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor. Oncogene. 2025;44:2515\u201329.","journal-title":"Oncogene"},{"key":"9104_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00018-024-05469-9","volume":"81","author":"D Sarkar","year":"2024","unstructured":"Sarkar D, Chakraborty A, Mandi S, Dutt S. PARylation of GCN5 by PARP1 mediates its recruitment to DSBs and facilitates both HR and NHEJ Repair. Cell Mol Life Sci. 2024;81:446.","journal-title":"Cell Mol Life Sci"},{"key":"9104_CR11","doi-asserted-by":"crossref","unstructured":"Zong W, Gong Y, Sun W, Li T, Wang ZQ. PARP1: Liaison of Chromatin Remodeling and Transcription. Cancers. 2022;14.","DOI":"10.3390\/cancers14174162"},{"key":"9104_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13072-024-00550-w","volume":"17","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Transcriptional regulation mechanism of PARP1 and its application in disease treatment. Epigenetics chromatin. 2024;17:26.","journal-title":"Epigenetics chromatin"},{"key":"9104_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","volume":"6","author":"F Wang","year":"2025","unstructured":"Wang F, Guo Z, Carr MJ, Shi W. PARPs and PARP inhibitors: molecular mechanisms and clinical applications. Mol biomedicine. 2025;6:152.","journal-title":"Mol biomedicine"},{"key":"9104_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-019-0042-0","volume":"4","author":"M Cohen-Armon","year":"2019","unstructured":"Cohen-Armon M, Yeheskel A, Pascal JM. Signal-induced PARP1-Erk synergism mediates IEG expression. Signal Transduct Target Ther. 2019;4:8.","journal-title":"Signal Transduct Target Ther"},{"key":"9104_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molcel.2006.12.012","volume":"25","author":"M Cohen-Armon","year":"2007","unstructured":"Cohen-Armon M, et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell. 2007;25:297\u2013308.","journal-title":"Mol Cell"},{"key":"9104_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tips.2007.08.005","volume":"28","author":"M Cohen-Armon","year":"2007","unstructured":"Cohen-Armon M. PARP-1 activation in the ERK signaling pathway. Trends Pharm Sci. 2007;28:556\u201360.","journal-title":"Trends Pharm Sci"},{"key":"9104_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-023-01428-2","volume":"16","author":"A Marranci","year":"2023","unstructured":"Marranci A, et al. PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation. J Hematol Oncol. 2023;16:33.","journal-title":"J Hematol Oncol"},{"key":"9104_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00018-024-05292-2","volume":"81","author":"X Fu","year":"2024","unstructured":"Fu X, et al. Poly (ADP-ribose) polymerase 1 promotes HuR\/ELAVL1 cytoplasmic localization and inflammatory gene expression by regulating p38 MAPK activity. Cell Mol Life Sci. 2024;81:253.","journal-title":"Cell Mol Life Sci"},{"key":"9104_CR19","doi-asserted-by":"crossref","unstructured":"Boehi F, Manetsch P, Hottiger MO. Interplay between ADP-ribosyltransferases and essential cell signaling pathways controls cellular responses. Cell Discov. 2021;7.","DOI":"10.1038\/s41421-021-00323-9"},{"key":"9104_CR20","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1134\/S0006297924120058","volume":"89","author":"A Emelyanova","year":"2024","unstructured":"Emelyanova A, et al. Activation of P38 MAPK Signaling Cascade is Linked with Clinical Outcomes and Therapeutic Responses in Human Cancers. Biochem Biokhimiia. 2024;89:2155\u201373.","journal-title":"Biochem Biokhimiia"},{"key":"9104_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbrc.2023.05.116","volume":"670","author":"P Dey","year":"2023","unstructured":"Dey P, Biswas S, Das R, Chatterjee S, Ghosh U. p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic way on non-small cell lung carcinoma A549 cells. Biochem Biophys Res Commun. 2023;670:55\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"9104_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41392-022-01131-7","volume":"7","author":"GN Li","year":"2022","unstructured":"Li GN, et al. Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. Signal Transduct Target Ther. 2022;7:317.","journal-title":"Signal Transduct Target Ther"},{"key":"9104_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45478-7","volume":"15","author":"J Dai","year":"2024","unstructured":"Dai J, et al. Tracing back primed resistance in cancer via sister cells. Nat Commun. 2024;15:1158.","journal-title":"Nat Commun"},{"key":"9104_CR24","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1217657110","volume":"110","author":"C Ding","year":"2013","unstructured":"Ding C, et al. Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. Proc Natl Acad Sci USA 2013;110:6771\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9104_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41556-019-0287-4","volume":"21","author":"T Nacarelli","year":"2019","unstructured":"Nacarelli T, et al. NAD(+) metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol. 2019;21:397\u2013407.","journal-title":"Nat Cell Biol"},{"key":"9104_CR26","doi-asserted-by":"publisher","first-page":"00","DOI":"10.2174\/1573394719666230817094831","volume":"20","author":"M Kumar","year":"2024","unstructured":"Kumar M, Kaur S, Kaur S. c-Jun N-terminal Kinase (JNK), p38, and Caspases: Promising Therapeutic Targets for the Regulation of Apoptosis in Cancer Cells by Phytochemicals. Curr Cancer Ther Rev. 2024;20:00\u2013211.","journal-title":"Curr Cancer Ther Rev"},{"key":"9104_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.freeradbiomed.2017.04.018","volume":"108","author":"E Hocsak","year":"2017","unstructured":"Hocsak E, et al. PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway. Free Radic Biol Med. 2017;108:770\u201384.","journal-title":"Free Radic Biol Med"},{"key":"9104_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41416-024-02894-2","volume":"132","author":"R Tan","year":"2025","unstructured":"Tan R, et al. Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets. Br J Cancer. 2025;132:111\u201325.","journal-title":"Br J Cancer"},{"key":"9104_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50786-z","volume":"15","author":"L Qian","year":"2024","unstructured":"Qian L, et al. Proteomic landscape of epithelial ovarian cancer. Nat Commun. 2024;15:6462.","journal-title":"Nat Commun"},{"key":"9104_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111062","volume":"116","author":"Y Sun","year":"2024","unstructured":"Sun Y, et al. IKBKE promotes the ZEB2-mediated EMT process by phosphorylating HMGA1a in glioblastoma. Cell Signal. 2024;116:111062.","journal-title":"Cell Signal"},{"key":"9104_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1471-4159.2000.0740392.x","volume":"74","author":"DM Xiao","year":"2000","unstructured":"Xiao DM, et al. Phosphorylation of HMG-I by protein kinase C attenuates its binding affinity to the promoter regions of protein kinase C gamma and neurogranin\/RC3 genes. J Neurochemistry. 2000;74:392\u201399.","journal-title":"J Neurochemistry"},{"key":"9104_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1101\/gad.335109.119","volume":"34","author":"MS Cohen","year":"2020","unstructured":"Cohen MS. Interplay between compartmentalized NAD(+) synthesis and consumption: a focus on the PARP family. Genes Dev. 2020;34:254\u201362.","journal-title":"Genes Dev"},{"key":"9104_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30:563\u201377.","journal-title":"Cancer Cell"},{"key":"9104_CR34","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1038\/s41586-018-0722-x","volume":"565","author":"J Barretina","year":"2019","unstructured":"Barretina J, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019;565:E5\u20136.","journal-title":"Nature"},{"key":"9104_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57506-9","volume":"10","author":"A Wilk","year":"2020","unstructured":"Wilk A, et al. Extracellular NAD(+) enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci Rep. 2020;10:651.","journal-title":"Sci Rep"},{"key":"9104_CR36","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1016\/j.molcel.2024.10.024","volume":"84","author":"MF Langelier","year":"2024","unstructured":"Langelier MF, et al. PARP enzyme de novo synthesis of protein-free poly(ADP-ribose). Mol Cell. 2024;84:4758\u201373.e4756.","journal-title":"Mol Cell"},{"key":"9104_CR37","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1039\/D1SC06256E","volume":"13","author":"XN Zhang","year":"2022","unstructured":"Zhang XN, et al. Discovery of an NAD(+) analogue with enhanced specificity for PARP1. Chem Sci. 2022;13:1982\u201391.","journal-title":"Chem Sci"},{"key":"9104_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15089","volume":"8","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, et al. A mouse tissue transcription factor atlas. Nat Commun. 2017;8:15089.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09104-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09104-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09104-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:12:15Z","timestamp":1791825135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09104-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9104"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09104-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All experimental procedures were conducted in accordance with relevant institutional guidelines and regulations. The collection and use of human ovarian samples were approved by the Medical Ethics Committee of Xiangya Hospital, Central South University (202507081). Written informed consent was obtained from all participants prior to tissue collection.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"880"}}